We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generics Maker ECI Receives Warning Letter for Incorrectly Listing Its Products
Generics Maker ECI Receives Warning Letter for Incorrectly Listing Its Products
Fort Lauderdale, Fla.-based ECI Pharmaceuticals has received a warning letter from the FDA, which said the generic drugmaker incorrectly listed two hormone products on FDA’s Drug Registration and Listing System (eDRLS), and of misbranding.